COVID-19 Pandemic and the Debatable Use of Hydroxychloroquine
Abstract
Healthcare professionals and scientists were not able to provide a good answer to the COVID-19 pandemic that shook the whole world. Hydroxychloroquine is an antimalarial drug with a good safety profile. It can be used in pediatric subjects as well as pregnant and breastfeeding women. Hydroxychloroquine is a widely used, essential drug in dermatology. It has got anti-inflammatory, antibacterial, antiviral and immunomodulatory properties. It was globally prescribed to prevent and treat COVID-19 caused by SARS-CoV-2 virus. The use of this drug in treating COVID-19 is debatable and for sure is not indicated in the labelling documents provided by the companies that manufacture this drug. The unnecessary use of this drug also led to short supply. We hereby review its properties, mechanism, safety profile and the issue COVID pandemic has caused to the supply of this drug.
Downloads
References
Fernandez AP. Updated recommendations on the use of hydroxychloroquine in dermatologic practice. J Am Acad Dermatol.2017;76:1176-82.
Chew CY, Mar A, Nikpour M, Saracino AM. Hydroxychloroquine in dermatology: New perspectives on an old drug. Australas J Dermatol. 2020;61:e150-7.
Sardana K, Sinha S, Sachdeva S. Hydroxychloroquine in dermatology and beyond: Recent update. Indian Dermatol Online J.2020;11:453-64.
Cox S. To dispense or not to dispense: Lessons to be learnt from ethical challenges faced by pharmacists in the COVID-19 pandemic. Dev World Bioeth. 2020. https://doi.org/10.1111/dewb.12284
Baral S, Rao A, Rwema JOT, Lyons C, Cevik M, Kågesten AE,et al. Competing health risks associated with the COVID-19 pandemic and response: A scoping review. medRxiv.
Melles RB, Marmor MF. The risk of toxic retinopathy in patients on long-term hydroxychloroquine therapy. JAMA Ophthalmol.2014;132:1453-60.
Mohammad S, Clowse MEB, Eudy AM, Criscione-Schreiber LG. Examination of hydroxychloroquine use and hemolytic anemia in G6PDH-deficient patients. Arthritis Care Res (Hoboken).2018;70:481-5.
Ortega-Pena M, González-Cuevas R. Familiar dermatolo-gic drugs as therapies for COVID-19. Actas Dermosifiliogr.2021;112:118---26.
Stojkovic-Filipovic J, Bosic M. Treatment of COVID 19-repurposing drugs commonly used in dermatology. Dermatol Ther. 2020;33:e13829.
Choudhuri AH, Duggal S, Ahuja B, Biswas PS. The efficacy and safety of hydroxychloroquine (HCQ) in treatment of COVID19 - a systematic review and meta-analysis. Indian J Med Microbiol.2021, http://dx.doi.org/10.1016/j.ijmmb.2021.03.002.50.
Mendel A, Bernatsky S, Askanase A, Bae S-C, Clarke AE,Costedoat-Chalumeau N, et al. Hydroxychloroquine shortages among patients with systemic lupus erythematosus during theCOVID-19 pandemic: Experience of the Systemic Lupus Interna-tional Collaborating Clinics. Ann Rheum Dis. 2021;80:1-2.
Shah M, Sachdeva M, Dodiuk-Gad RP. The impact of hydroxychloroquine shortages on patients with dermatological conditions during COVID-19 pandemic. Dermatol Ther. 2020;33:e13524.
Peschken CA. Possible consequences of a shortage of hydroxychloroquine for patients with systemic lupus erythematosus amid the COVID-19 pandemic. J Rheumatol. 2020;47:787-90.
Singh B, Ryan H, Kredo T, Chaplin M, Fletcher T. Chloroquine orhydroxychloroquine for prevention and treatment of COVID-19.Cochrane Database Syst Rev. 2021;2:CD013587.
Mitjà O, Corbacho-Monné M, Ubals M, Alemany A, Suner C, Tebé C et al. A cluster-randomized trial of hydroxychloroquine for prevention of Covid-19. N Engl J Med. 2021;384:417-27.10
Copyright (c) 2021 Yashika Kaushal et al.
This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License.
